Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast echographic response study in active psoriatic arthritis
2017-000901-19Phase 3Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Vall d'Hebron Research Institute. Started Aug 2017; status: active.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-000901-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000901-19.